Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Experience of Anti-PD-1 Immunotherapy Plus Chemotherapy as First-line Treatment for Patients With Advanced Oesophageal Squamous Cell Carcinoma in China(REACTION Trial).

NCT05142709 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05142709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05142709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Experience of Anti-PD-1 Immunotherapy Plus Chemotherapy as First-line Treatment for Patients With Advanced Oesophageal Squamous Cell Carcinoma in China(REACTION Trial).
Lead sponsor
Fudan University
Phase
Observational
Overall status
Completed
Start date
October 31, 2021
Completion date
December 31, 2025
Enrollment
1,197 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic esophageal squamous cell carcinoma